[HTML][HTML] Assessment of tocilizumab (anti–interleukin-6 receptor monoclonal) as a potential treatment for chronic antibody-mediated rejection and transplant …
J Choi, O Aubert, A Vo, A Loupy, M Haas… - American Journal of …, 2017 - Elsevier
Extending the functional integrity of renal allografts is the primary goal of transplant
medicine. The development of donor-specific antibodies (DSAs) posttransplantation leads to
chronic active antibody-mediated rejection (cAMR) and transplant glomerulopathy (TG),
resulting in the majority of graft losses that occur in the United States. This reduces the
quality and length of life for patients and increases cost. There are no approved treatments
for cAMR. Evidence suggests the proinflammatory cytokine interleukin 6 (IL-6) may play an …
medicine. The development of donor-specific antibodies (DSAs) posttransplantation leads to
chronic active antibody-mediated rejection (cAMR) and transplant glomerulopathy (TG),
resulting in the majority of graft losses that occur in the United States. This reduces the
quality and length of life for patients and increases cost. There are no approved treatments
for cAMR. Evidence suggests the proinflammatory cytokine interleukin 6 (IL-6) may play an …